Ancora Advisors’s Sage Therapeutics SAGE Stock Holding History

Ancora Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-75	Closed	-$814	–	1883
2024 Q2	$814	Hold	75	–	–	﹤0.01%	1671
2024 Q1	$1.41K	Hold	75	–	–	﹤0.01%	1595
2023 Q4	$1.63K	Sell	75 -100	-57%	-$1.98K	﹤0.01%	1505
2023 Q3	$3.6K	Hold	175	–	–	﹤0.01%	1431
2023 Q2	$8.23K	Hold	175	–	–	﹤0.01%	1316
2023 Q1	$7.34K	Sell	175 -10	-5%	-$430	﹤0.01%	1339
2022 Q4	$7K	Hold	185	–	–	﹤0.01%	1425
2022 Q3	$7K	Buy	185 +10	+6%	+$387	﹤0.01%	1582
2022 Q2	$5K	Sell	175 -19	-10%	-$637	﹤0.01%	1766
2022 Q1	$6K	Buy	194 +19	+11%	+$714	﹤0.01%	1907
2021 Q4	$7K	Hold	175	–	–	﹤0.01%	1938
2021 Q3	$7K	Hold	175	–	–	﹤0.01%	1813
2021 Q2	$10K	Hold	175	–	–	﹤0.01%	1530
2021 Q1	$13K	Hold	175	–	–	﹤0.01%	1398
2020 Q4	$15K	Hold	175	–	–	﹤0.01%	1124
2020 Q3	$11K	Hold	175	–	–	﹤0.01%	1131
2020 Q2	$7K	Hold	175	–	–	﹤0.01%	1166
2020 Q1	$5K	Sell	175 -30	-15%	-$1.74K	﹤0.01%	1287
2019 Q4	$15K	Buy	+205	New	+$25.2K	﹤0.01%	1113

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Ancora Advisors's SAGE Position: Q3 2024 in Review

Ancora Advisors sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 75 shares — an estimated $814 sold.

Ancora Advisors first reported a position in SAGE in Q4 2019 and held it in 19 quarters. The position peaked at $15K in Q4 2020. 176 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

Ancora Advisors reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
Ancora Advisors sold 75 Sage Therapeutics shares in Q3 2024, an estimated $814.
Ancora Advisors first reported a position in Sage Therapeutics in Q4 2019 and held it in 19 quarters.
Ancora Advisors's Sage Therapeutics position peaked at $15K in Q4 2020.
176 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on Ancora Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.